How is it best to treat early rheumatoid arthritis patients?

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

During the past decade, many important changes have occurred in the treatment of rheumatoid arthritis, perhaps the most important of which has been the realization that early diagnosis and early treatment are critical. This has challenged our health-care systems to make sure that patients with early arthritis have access to the appropriate physicians. Additionally, the last decade has also seen many new treatment options become available for patients with rheumatoid arthritis. These new options have included the use of old drugs more effectively; the use of combinations of two or more disease-modifying anti-rheumatic drugs; new evidence to support the use of steroids; the resurrection of tetracyclines; the introduction of leflunomide; and, finally, the tumour necrosis factor inhibitors etanercept and infliximab. The availability of all these new options is clearly excellent news for patients with RA and their physicians. It is hoped that we will, in the next few years, better understand how most effectively to utilize these treatment options for the optimal care of our patients.

Original languageEnglish (US)
Pages (from-to)125-137
Number of pages13
JournalBest Practice and Research: Clinical Rheumatology
Volume15
Issue number1
DOIs
StatePublished - Jan 1 2001

Fingerprint

Rheumatoid Arthritis
leflunomide
Physicians
Tetracyclines
Antirheumatic Agents
Therapeutics
Arthritis
Early Diagnosis
Patient Care
Tumor Necrosis Factor-alpha
Steroids
Delivery of Health Care
Pharmaceutical Preparations

Keywords

  • Biologicals
  • Early
  • Minocycline
  • Prognosis
  • Rheumatoid arthritis
  • Treatment

ASJC Scopus subject areas

  • Rheumatology

Cite this

How is it best to treat early rheumatoid arthritis patients? / O'Dell, James Robert.

In: Best Practice and Research: Clinical Rheumatology, Vol. 15, No. 1, 01.01.2001, p. 125-137.

Research output: Contribution to journalArticle

@article{4a5af26b90ab4873a16b472f652d4f9a,
title = "How is it best to treat early rheumatoid arthritis patients?",
abstract = "During the past decade, many important changes have occurred in the treatment of rheumatoid arthritis, perhaps the most important of which has been the realization that early diagnosis and early treatment are critical. This has challenged our health-care systems to make sure that patients with early arthritis have access to the appropriate physicians. Additionally, the last decade has also seen many new treatment options become available for patients with rheumatoid arthritis. These new options have included the use of old drugs more effectively; the use of combinations of two or more disease-modifying anti-rheumatic drugs; new evidence to support the use of steroids; the resurrection of tetracyclines; the introduction of leflunomide; and, finally, the tumour necrosis factor inhibitors etanercept and infliximab. The availability of all these new options is clearly excellent news for patients with RA and their physicians. It is hoped that we will, in the next few years, better understand how most effectively to utilize these treatment options for the optimal care of our patients.",
keywords = "Biologicals, Early, Minocycline, Prognosis, Rheumatoid arthritis, Treatment",
author = "O'Dell, {James Robert}",
year = "2001",
month = "1",
day = "1",
doi = "10.1053/berh.2000.0130",
language = "English (US)",
volume = "15",
pages = "125--137",
journal = "Best Practice and Research in Clinical Rheumatology",
issn = "1521-6942",
publisher = "Bailliere Tindall Ltd",
number = "1",

}

TY - JOUR

T1 - How is it best to treat early rheumatoid arthritis patients?

AU - O'Dell, James Robert

PY - 2001/1/1

Y1 - 2001/1/1

N2 - During the past decade, many important changes have occurred in the treatment of rheumatoid arthritis, perhaps the most important of which has been the realization that early diagnosis and early treatment are critical. This has challenged our health-care systems to make sure that patients with early arthritis have access to the appropriate physicians. Additionally, the last decade has also seen many new treatment options become available for patients with rheumatoid arthritis. These new options have included the use of old drugs more effectively; the use of combinations of two or more disease-modifying anti-rheumatic drugs; new evidence to support the use of steroids; the resurrection of tetracyclines; the introduction of leflunomide; and, finally, the tumour necrosis factor inhibitors etanercept and infliximab. The availability of all these new options is clearly excellent news for patients with RA and their physicians. It is hoped that we will, in the next few years, better understand how most effectively to utilize these treatment options for the optimal care of our patients.

AB - During the past decade, many important changes have occurred in the treatment of rheumatoid arthritis, perhaps the most important of which has been the realization that early diagnosis and early treatment are critical. This has challenged our health-care systems to make sure that patients with early arthritis have access to the appropriate physicians. Additionally, the last decade has also seen many new treatment options become available for patients with rheumatoid arthritis. These new options have included the use of old drugs more effectively; the use of combinations of two or more disease-modifying anti-rheumatic drugs; new evidence to support the use of steroids; the resurrection of tetracyclines; the introduction of leflunomide; and, finally, the tumour necrosis factor inhibitors etanercept and infliximab. The availability of all these new options is clearly excellent news for patients with RA and their physicians. It is hoped that we will, in the next few years, better understand how most effectively to utilize these treatment options for the optimal care of our patients.

KW - Biologicals

KW - Early

KW - Minocycline

KW - Prognosis

KW - Rheumatoid arthritis

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0035046913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035046913&partnerID=8YFLogxK

U2 - 10.1053/berh.2000.0130

DO - 10.1053/berh.2000.0130

M3 - Article

C2 - 11358419

AN - SCOPUS:0035046913

VL - 15

SP - 125

EP - 137

JO - Best Practice and Research in Clinical Rheumatology

JF - Best Practice and Research in Clinical Rheumatology

SN - 1521-6942

IS - 1

ER -